CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Safety and tolerability of combinations of empagliflozin/linagliptin for 52 weeks in patients with type 2 diabetes
DOI 10.1055/s-0036-1580791
Bibliografische Angaben
Nachweis in CareLit
Autor:innenS Patel, R De Fronzo, A Lewin, R Kaste, S Kohler, HJ Woerle, UC Broedl
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe04/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aim: To assess the safety and tolerability of empagliflozin/linagliptin in subjects with type 2 diabetes (T2DM) using pooled Phase III trial data. Methods: Data were pooled from two 52-week Phase III studies in which patients received empagliflozin 25 mg/linagliptin 5 mg (n = 273), empagliflozin 10 mg/linagliptin 5 mg (n = 272), empagliflozin 25 mg (n = 276), empagliflozin 10 mg (n = 275) or linagliptin 5 mg (n = 26…
Zitieren
Zitierempfehlung
S Patel, R De Fronzo, A Lewin, R Kaste, S Kohler, HJ Woerle, UC Broedl (2016) Safety and tolerability of combinations of empagliflozin/linagliptin for 52 weeks in patients with type 2 diabetes. Diabetologie und Stoffwechsel (04). https://doi.org/10.1055/s-0036-1580791
Mit CareLit weiterarbeiten